Inhibition of ODC by α-difluoromethylornithine (DFMO) decreased ArgI production in MDSCs consequently DFMO treated MDSCs failed to retain their suppressive activity which led to slower tumor growth in wild type mice but not in Rag1−/− immunodeficient mice suggesting that DFMO treatment augments antitumor immunity via modulation of ODC in MDSCs [209] (Table 5). Here, LNCARGI is linked to neoplasm.